Precision oncology framework for investigation of exercise as treatment for cancer

Journal of Clinical Oncology

Volumn 33, Issue 35, 2015, Pages 4134-4137

  Jones, Lee W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN RECEPTOR;

BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CIRCULATING TUMOR CELL; DRUG SCREENING; EXOSOME; HUMAN; KINESIOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR EPIDEMIOLOGY; MULTICENTER STUDY (TOPIC); NONHUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK REDUCTION; CLINICAL TRIAL (TOPIC); EXERCISE; NEOPLASMS; ONCOLOGY; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

CLINICAL TRIALS AS TOPIC; EXERCISE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRECISION MEDICINE;

EID: 84951170661     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.7687     Document Type: Note

References (40)

1. Meric-Bernstam F, Brusco L, Shaw K, et al: Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33:2753-2762, 2015
2. Tsimberidou AM, Eggermont AM, Schilsky RL: Precision cancer medicine: The future is now, only better. Am Soc Clin Oncol Educ Book 61-69, 2014
3. Meric-Bernstam F, Johnson A, Holla V, et al: A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107:pii: djv098, 2015
4. Mendelsohn J: Personalizing oncology: Perspectives and prospects. J Clin Oncol 31:1904-1911, 2013
5. Hawk ET, Greenwood A, Gritz ER, et al: The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res 14:5707-5713, 2008
6. Marrone M, Schilsky RL, Liu G, et al: Opportunities for translational epidemiology: The important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev 24:484-489, 2015
7. Holmes MD, Chen WY, Feskanich D, et al: Physical activity and survival after breast cancer diagnosis. JAMA 293:2479-2486, 2005
8. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 24:3535-3541, 2006
9. Meyerhardt JA, Giovannucci EL, Holmes MD, et al: Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 24:3527-3534, 2006
10. Richman EL, Kenfield SA, Stampfer MJ, et al: Physical activity after diagnosis and risk of prostate cancer progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Res 71:3889-3895, 2011
11. Vineis P: Causality assessment in epidemiology. Theor Med 12:171-181, 1991
12. Zhong S, Jiang T, Ma T, et al: Association between physical activity and mortality in breast cancer: A meta-analysis of cohort studies. Eur J Epidemiol 29:391-404, 2014
13. Ibrahim EM, Al-Homaidh A: Physical activity and survival after breast cancer diagnosis: Meta-analysis of published studies. Med Oncol 28:753-765, 2011
14. Potter JD: The failure of cancer chemoprevention. Carcinogenesis 35:974-982, 2014
15. Byers T: Anticancer vitamins du jour: The ABCED's so far. Am J Epidemiol 172:1-3, 2010
16. Ioannidis JP: Implausible results in human nutrition research. BMJ 347:f6698, 2013
17. Ballard-Barbash R, Friedenreich CM, Courneya KS, et al: Physical activity, biomarkers, and disease outcomes in cancer survivors: A systematic review. J Natl Cancer Inst 104:815-840, 2012
18. Yamauchi M, Lochhead P, Imamura Y, et al: Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev 22:1142-1152, 2013
19. Morikawa T, Kuchiba A, Yamauchi M, et al: Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305:1685-1694, 2011
20. Meyerhardt JA, Ogino S, Kirkner GJ, et al: Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res 15:5931-5936, 2009
21. Stahel R, Bogaerts J, Ciardiello F, et al: Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treat Rev 41:129-135, 2015
22. Rodon J, Soria JC, Berger R, et al: Challenges in initiating and conducting personalized cancer therapy trials: Perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol 26:1791-1798, 2015
23. Gould SE, Junttila MR, de Sauvage FJ: Translational value of mouse models in oncology drug development. Nat Med 21:431-439, 2015
24. Sharpless NE, Depinho RA: The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741-754, 2006
25. White R, Rose K, Zon L: Zebrafish cancer: The state of the art and the path forward. Nat Rev Cancer 13:624-636, 2013
26. Gonzalez C: Drosophila melanogaster: A model and a tool to investigate malignancy and identify new therapeutics. Nat Rev Cancer 13:172-183, 2013
27. Betof AS, Dewhirst MW, Jones LW: Effects and potential mechanisms of exercise training on cancer progression: A translational perspective. Brain Behav Immun 30:S75-S87, 2013
28. US Department of Health and Human Services, Food and Drug Administration: Guidance for Industry: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, 2010
29. Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J 22:659-661, 2008
30. Hawley JA, Hargreaves M, Joyner MJ, et al: Integrative biology of exercise. Cell 159:738-749, 2014
31. Jones LW, Eves ND, Haykowsky M, et al: Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 10:598-605, 2009
32. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001
33. Kenjale AA, Hornsby WE, Crowgey T, et al: Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients. Oncologist 19:999-1005, 2014
34. Ratain MJ, Schilsky RL, Conley BA, et al: Pharmacodynamics in cancer therapy. J Clin Oncol 8:1739-1753, 1990
35. Sasso JP, Eves ND, Christensen JF, et al: A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 6:115-124, 2015
36. Diaz LA Jr, Bardelli A: Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 32:579-586, 2014
37. Redig AJ, Jänne PA: Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 33:975-977, 2015
38. Courneya KS, Booth CM, Gill S, et al: The Colon Health and Life-Long Exercise Change trial: A randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol 15:279-285, 2008
39. O'Connor CM, Whellan DJ, Lee KL, et al: Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301:1439-1450, 2009
40. Whellan DJ, O'Connor CM, Lee KL, et al: Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): Design and rationale. Am Heart J 153:201-211, 2007